Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! View ALL results for your Stocks, ETFs and Funds Screeners with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Adverum Biotechnologies Inc (ADVM)

Adverum Biotechnologies Inc (ADVM)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Adverum Biotechnologies: Q4 Earnings Snapshot

Adverum Biotechnologies: Q4 Earnings Snapshot

ADVM : 10.19 (-7.36%)
Adverum Biotechnologies: Q3 Earnings Snapshot

Adverum Biotechnologies: Q3 Earnings Snapshot

ADVM : 10.19 (-7.36%)
Adverum Biotechnologies: Q2 Earnings Snapshot

Adverum Biotechnologies: Q2 Earnings Snapshot

ADVM : 10.19 (-7.36%)
Adverum Biotechnologies: Q1 Earnings Snapshot

Adverum Biotechnologies: Q1 Earnings Snapshot

ADVM : 10.19 (-7.36%)
Is Adial Pharmaceuticals (ADIL) Stock Outpacing Its Medical Peers This Year?

Here is how Adial Pharmaceuticals, Inc. (ADIL) and Adverum Biotechnologies (ADVM) have performed compared to their sector so far this year.

ADIL : 1.7100 (+0.59%)
ADVM : 10.19 (-7.36%)
Rumble, Braze rise; Virgin Orbit, Sientra fall

Stocks that traded heavily or had substantial price changes Friday: Rumble, Braze rise; Virgin Orbit, Sientra fall

ADVM : 10.19 (-7.36%)
SIEN : 0.1740 (-18.69%)
BB.TO : 3.95 (-0.50%)
NKLA : 0.6200 (-2.41%)
Adverum Biotechnologies: Q4 Earnings Snapshot

Adverum Biotechnologies: Q4 Earnings Snapshot

ADVM : 10.19 (-7.36%)
Adverum Biotechnologies: Q3 Earnings Snapshot

Adverum Biotechnologies: Q3 Earnings Snapshot

ADVM : 10.19 (-7.36%)
Adverum (ADVM) Doses First Patient in the Mid-Stage wAMD Study

Adverum (ADVM) initiates dosing in the phase II LUNA study, currently investigating its lead product candidate ixoberogene soroparvovec for wet age-related macular degeneration.

REGN : 906.54 (-0.09%)
DVAX : 11.42 (-2.89%)
BAYRY : 7.2600 (-1.49%)
ADVM : 10.19 (-7.36%)
Adverum Biotechnologies to Participate in the 2nd Annual H.C. Wainwright Ophthalmology Virtual Conference

REDWOOD CITY, Calif., Aug. 10, 2022 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company that aims to establish...

ADVM : 10.19 (-7.36%)

Barchart Exclusives

3 Dividend Aristocrats to Buy on Every Dip
As markets get wobbly, here are three Dividend Aristocrats to add a little stability to any portfolio. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar